Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Not yet recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
This study will explore the effectiveness and safety of the combination therapy of anlotinib
, penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)